Latest Conference Articles

September 21st 2020, 10:33pm

ESMO Congress

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

September 21st 2020, 10:23pm

ESMO Congress

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

September 21st 2020, 9:40pm

ESMO Congress

The feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demonstrated in the phase 1b TRAMUNE trial.

September 21st 2020, 9:00pm

ESMO Congress

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.

September 21st 2020, 8:00pm

ESMO Congress

Pembrolizumab monotherapy prolonged progression-free survival in selected rare sarcoma subtypes, supporting the immune checkpoint inhibitor’s ability to improve outcomes across histotypes.

September 21st 2020, 6:55pm

ESMO Congress

Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.

September 21st 2020, 6:00pm

ESMO Congress

Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.

September 21st 2020, 4:55pm

ESMO Congress

Osimertinib reduced the risk for central nervous system death or progression by 82% in patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection.

September 21st 2020, 4:30pm

ESMO Congress

Frontline pembrolizumab plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.

September 20th 2020, 10:45pm

ESMO Congress

Lenvatinib plus pembrolizumab showed early antitumor activity and tolerability in previously treated patients with advanced solid tumors.

September 20th 2020, 10:35pm

ESMO Congress

Ipatasertib combined with abiraterone acetate plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity compared with placebo plus abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer with PTEN loss.

September 20th 2020, 10:20pm

ESMO Congress

Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.

September 20th 2020, 10:10pm

ESMO Congress

BLU-945, an investigational precision therapy, elicited robust antitumor activity in multiple preclinical models of triple-mutated EGFR-positive non–small cell lung cancer .

September 20th 2020, 9:50pm

ESMO Congress

The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.

September 20th 2020, 9:45pm

ESMO Congress

Zarnie Lwin, MBBS, FRACP, discusses the results of the LEAP-005 trial in advanced solid tumors.

September 20th 2020, 9:07pm

ESMO Congress

Stephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.

September 20th 2020, 8:45pm

ESMO Congress

Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.

September 20th 2020, 8:20pm

ESMO Congress

Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

September 20th 2020, 7:38pm

ESMO Congress

Potent and durable clinical activity was shown with pralsetinib as treatment of patients with RET-mutant advanced medullary thyroid cancer, regardless of the line of therapy.

September 20th 2020, 6:21pm

ESMO Congress

The combination of amivantamab and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib-resistant patients with advanced EGFR-mutant non–small cell lung cancer.